View in EDS

Immunogenicity and safety of fractional doses of 17D-213 yellow fever vaccine in HIV-infected people in Kenya (YEFE): a randomised, double-blind, non-inferiority substudy of a phase 4 trial.

Saved in:
Bibliographic Details
Title: Immunogenicity and safety of fractional doses of 17D-213 yellow fever vaccine in HIV-infected people in Kenya (YEFE): a randomised, double-blind, non-inferiority substudy of a phase 4 trial.
Authors: Kimathi D; Kenya Medical Research Institute-Wellcome Trust Research Programme, Kilifi, Kenya; Centre for Tropical Medicine & Global Health, University of Oxford, Oxford, UK., Juan-Giner A; Epicentre, Paris, France., Orindi B; Kenya Medical Research Institute-Wellcome Trust Research Programme, Kilifi, Kenya., Grantz KH; Department of Biology and Emerging Pathogens Institute, University of Florida, Gainesville, FL, USA; Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA., Bob NS; Institut Pasteur Dakar, Dakar, Senegal., Cheruiyot S; Kenya Medical Research Institute-Wellcome Trust Research Programme, Kilifi, Kenya., Hamaluba M; Kenya Medical Research Institute-Wellcome Trust Research Programme, Kilifi, Kenya; Centre for Tropical Medicine & Global Health, University of Oxford, Oxford, UK., Kamau N; Kenya Medical Research Institute-Wellcome Trust Research Programme, Kilifi, Kenya., Fall G; Institut Pasteur Dakar, Dakar, Senegal., Dia M; Institut Pasteur Dakar, Dakar, Senegal., Mosobo M; Kenya Medical Research Institute-Wellcome Trust Research Programme, Kilifi, Kenya., Moki F; Kenya Medical Research Institute-Wellcome Trust Research Programme, Kilifi, Kenya., Kiogora K; Kenya Medical Research Institute-Wellcome Trust Research Programme, Kilifi, Kenya., Chirro O; Kenya Medical Research Institute-Wellcome Trust Research Programme, Kilifi, Kenya., Thiong'o A; Kenya Medical Research Institute-Wellcome Trust Research Programme, Kilifi, Kenya., Mwendwa J; Kenya Medical Research Institute-Wellcome Trust Research Programme, Kilifi, Kenya., Guantai A; Kenya Medical Research Institute-Wellcome Trust Research Programme, Kilifi, Kenya., Karanja HK; Kenya Medical Research Institute-Wellcome Trust Research Programme, Kilifi, Kenya., Gitonga J; Kenya Medical Research Institute-Wellcome Trust Research Programme, Kilifi, Kenya., Mugo D; Kenya Medical Research Institute-Wellcome Trust Research Programme, Kilifi, Kenya., Ramko K; Kenya Medical Research Institute-Wellcome Trust Research Programme, Kilifi, Kenya., Faye O; Institut Pasteur Dakar, Dakar, Senegal., Sanders EJ; Kenya Medical Research Institute-Wellcome Trust Research Programme, Kilifi, Kenya; Centre for Tropical Medicine & Global Health, University of Oxford, Oxford, UK., Grais RF; Epicentre, Paris, France., Bejon P; Kenya Medical Research Institute-Wellcome Trust Research Programme, Kilifi, Kenya; Centre for Tropical Medicine & Global Health, University of Oxford, Oxford, UK., Warimwe GM; Kenya Medical Research Institute-Wellcome Trust Research Programme, Kilifi, Kenya; Centre for Tropical Medicine & Global Health, University of Oxford, Oxford, UK. Electronic address: gwarimwe@kemri-wellcome.org.
Source: The Lancet. Infectious diseases [Lancet Infect Dis] 2023 Aug; Vol. 23 (8), pp. 974-982. Date of Electronic Publication: 2023 Apr 28.
Publication Type: Clinical Trial, Phase IV; Equivalence Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Elsevier Science Country of Publication: United States NLM ID: 101130150 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1474-4457 (Electronic) Linking ISSN: 14733099 NLM ISO Abbreviation: Lancet Infect Dis Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1474-4457
DOI:10.1016/S1473-3099(23)00114-7